flow trial semaglutide kidney outcomes nejm 2024 hazard ratio 0.76 reduced the risk of clinically important and death from cardiovascular (CV) causes in patients with type 2 diabetes (T2D) and CKD ca. #ERA24 🇸🇪 #Nephpearls https://www.nejm .org/doi/full/10.1056/NEJMoa2403347 Effects of Semaglutide on Heart

Gastrointestinal side effects from GLP-1 therapy (nausea, constipation) may feel more pronounced if your stomach acid is already reduced

What to verify semaglutide, cash price and coverage terms How to use it Use this information to prepare sharper questions for a licensed provider

this is exactly why post market tracking needs to be way more solid

Building on the findings from the SURMOUNT-OSA trial, which demonstrated tirzepatides efficacy in improving OSA in nondiabetic patients, this study investigated whether OSA modifies the mortality benefit associated with GLP-1 use among individuals with diabetes in a large, real-world population

The pharmacokinetic properties including intestinal permeability, first-pass metabolism, microbiota-mediated biotransformation, plasma half-life, and systemic availability is essential for translational relevance

Conversely, if you experience early-morning nausea from any medications, evening injection avoids compounding that natural pattern